Why Im Not Arbing The Fresenius Akorn Deal | Latest News RSS feed
Why Im Not Arbing The Fresenius Akorn Deal - Latest News
Why I'm Not Arbing The Fresenius / Akorn Deal
I am not interested in risk-arbing this deal at the current risk/reward profile (6.25% in 1 year). The deal continues to make sense from a strategic perspective for Fresenius, but I think Akorn has si... read more
Corruption Currents: Trump Asserts ‘Absolute Immunity’ in Emoluments Lawsuit
(AM ... if she is not indicted on charges of misusing government funds. (Haaretz) Court documents made public this week show Germany-based healthcare company Fresenius Medical Care & Co. said it found ... read more
Can Akorn Win Its Fight Against Fresenius?
Akorn Inc. (NASDAQ: AKRX) shares were crushed on Monday (although not as bad as at Prothena ... but who will win is still yet to be seen. Fresenius said Sunday it would terminate the $4.3 billion deal ... read more
Looking for another news?
Fresenius says Akorn deal closure could take until next year (FRE, AKRX, FME)
FRANKFURT, Nov 22 (Reuters) - German healthcare group Fresenius SE said the planned takeover of Akorn , a U.S. maker of liquid generic drugs, might not be completed before ... that the rationale behin... read more
Akorn was warned about problems that scotched $4.3B Fresenius deal, exec testifies
Fresenius accused of nixing $4.3B deal ... the Akorn scientists were following company procedure in setting up tests. “I wouldn't call it fraud — that means they had malicious intent,'' she said. “If ... read more
Has Akorn Put The Worst Behind It?
In April of this year, the German pharmaceutical firm terminated its agreement to acquire Akorn. With Fresenius walking away from the merger deal, jilted Akron filed a complaint in Delaware Chancery C... read more
Why Diana Shipping, Akorn, and Granite Construction Jumped Today
But if JPMorgan is right, then a greater level of confidence in the shipping industry could lead to further gains not just for ... Already, Fresenius has made some strategic purchases within Europe, b... read more
Akorn Craters 32% On FDA Probe - Time To Buy?
The company announces a probe by Acquirer Fresenius amid FDA allegations. Akorn says it sees no material issues and the deal should ... so I am likely a daytrader in the name looking for some bounce-b... read more
Stada Gobbled Up by Private Investors
But today is really not the time to engage in ... Other recent deals saw Israel’s Teva Pharmaceuticals buy Allergan’s generic drug business. German company Fresenius is in talks to buy Akorn, another ... read more
Scancell's US focus underlined by change of chairman
"John has a wealth of international experience in this sector, particularly in the US, and I am confident that he will successfully guide the board and management team as the company embarks on the ne... read more
Why Akorn Shares Were Halved
Delaware’s Vice Chancellor Travis Laster noted that Fresenius validly terminated the merger agreement and he found Akorn’s representations regarding its compliance with regulatory requirements were “n... read more
Fresenius picks up M&A pace with Akorn, Merck KGaA deals
Berenberg analyst Tom Jones said the price tag of 12.4 times Akorn's core earnings (adjusted EBITDA) estimate for 2017 should not "give ... GMT (3.50 am ET), broadly in line with the European healthca... read more